BioCentury | Feb 13, 2020
Management Tracks

Head of digital, three other execs set to leave Sanofi as Hudson continues reorg

Five months into his tenure as CEO, Paul Hudson has trimmed Sanofi’s executive team back by four. The executives departing Sanofi (Euronext:SAN; NASDAQ:SNY) are EVP, Business Transformation Dominique Carouge; EVP, CMO and Chief Digital Officer...
BioCentury | Nov 15, 2019
Company News

BeiGene enters U.S. market with first approval for in-house pipeline

With its first approval for an internally developed drug, BeiGene faces tough competition as it seeks to carve out a niche for Brukinsa. But the third-to-market Btk inhibitor could have an edge on efficacy without...
BioCentury | Nov 9, 2019
Product Development

Amgen to accelerate China strategy via BeiGene deal

Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew. Through the deal...
BioCentury | May 17, 2019
Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
BioCentury | Feb 9, 2019
Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
BioCentury | Aug 23, 2006
Company News

Avantogen names Davanzo CFO

...Amgen (AMGN). She replaces interim CFO J. Lauro Valdovinos. AVTO recently changed its name from Innovate Oncology...
BioCentury | Jul 10, 2006
Company News

Innovate Oncology cancer news

...AVTO. The company also moved its headquarters to Los Angeles, Calif., from San Diego, Calif. Innovate Oncology Inc....
BioCentury | Feb 6, 2006
Company News

Avantogen, Innovate Oncology deal

...chemosensitizer, has completed Phase I/II trials to treat pancreatic cancer. Avantogen Ltd. (ASX:ACU), Sydney, Australia Innovate Oncology Inc....
BioCentury | Jun 27, 2005
Company News

Innovate Oncology board of directors update

Innovate Oncology Inc. (IOVO), New York, N.Y. Business: Cancer Appointed: Paul Hopper, former CEO of Avantogen Ltd., as chairman WIR Staff...
Items per page:
1 - 10 of 11
BioCentury | Feb 13, 2020
Management Tracks

Head of digital, three other execs set to leave Sanofi as Hudson continues reorg

Five months into his tenure as CEO, Paul Hudson has trimmed Sanofi’s executive team back by four. The executives departing Sanofi (Euronext:SAN; NASDAQ:SNY) are EVP, Business Transformation Dominique Carouge; EVP, CMO and Chief Digital Officer...
BioCentury | Nov 15, 2019
Company News

BeiGene enters U.S. market with first approval for in-house pipeline

With its first approval for an internally developed drug, BeiGene faces tough competition as it seeks to carve out a niche for Brukinsa. But the third-to-market Btk inhibitor could have an edge on efficacy without...
BioCentury | Nov 9, 2019
Product Development

Amgen to accelerate China strategy via BeiGene deal

Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew. Through the deal...
BioCentury | May 17, 2019
Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
BioCentury | Feb 9, 2019
Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
BioCentury | Aug 23, 2006
Company News

Avantogen names Davanzo CFO

...Amgen (AMGN). She replaces interim CFO J. Lauro Valdovinos. AVTO recently changed its name from Innovate Oncology...
BioCentury | Jul 10, 2006
Company News

Innovate Oncology cancer news

...AVTO. The company also moved its headquarters to Los Angeles, Calif., from San Diego, Calif. Innovate Oncology Inc....
BioCentury | Feb 6, 2006
Company News

Avantogen, Innovate Oncology deal

...chemosensitizer, has completed Phase I/II trials to treat pancreatic cancer. Avantogen Ltd. (ASX:ACU), Sydney, Australia Innovate Oncology Inc....
BioCentury | Jun 27, 2005
Company News

Innovate Oncology board of directors update

Innovate Oncology Inc. (IOVO), New York, N.Y. Business: Cancer Appointed: Paul Hopper, former CEO of Avantogen Ltd., as chairman WIR Staff...
Items per page:
1 - 10 of 11